
UPDATE: European Patent Issuance
The European Patent Office has allowed Application No. 16 854 445.0-1111 titled Recombinant Prothrombin Analogues and Uses Thereof that names Dr. Michael Kalafatis, a professor and Chair of the Department of Chemistry and a member of the Center for Gene Regulation in Health and Disease (GRHD). The inventive method comprises administering the polypeptide(s) of the general inventive concepts to a subject who has or is at risk of having arterial thrombosis.
Thrombosis is the formation of a blood clot inside a blood vessel, obstructing the flow of blood through the circulatory system. Arterial thrombosis means a blood clot formed in the artery which can be fatal. |
|

CSU Research Corporation
Annual Meeting
The CSU Research Corporation (CSURC) Board of Directors held their Annual Meeting on June 20, 2025 at the CSU-Transdigm Advanced Manufacturing Center. The Board was updated by Nigamanth Sridhar, President and CEO, Jack Kraszewski, COO and Executive Director, and Ben Ward, Director, Research Development & Ethics.
Several faculty research efforts and funding accomplishments were highlighted. All industry sponsored research collaborations administered by CSURC were also highlighted. The Directors were provided a tour of the new Center.
Contact Jack Kraszewski for information regarding the benefits of CSURC and technology transfer. |